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Neurodegeneration with Brain Iron Accumulation (NBIA) is a group of different rare disorders in which iron is accumulated in the 
brain, especially in the basal ganglia and substantia nigra. Prevalent symptoms are dystonia, spasticity and neuropsychiatric 
disorders. In the current study, we focused on Mitochondrial-membrane Protein-Associated Neurodegeneration (MPAN) which 
is a subtype of NBIA caused by  mutations in the C19orf12 gene. This gene encodes a protein located in the external membrane 
of the mitochondrial of unknown function. However, it is proposed that C19orf12 could be implicated in fatty acid biosynthesis, 
calcium exchange, coenzyme A biosynthesis or mitophagy. From a genetic point of view, the disease is autosomal-recessive, 
although cases of autosomal-dominant inheritance have been described.  
 
Motivation: Nowadays, there is not an effective treatment for these patients, therefore it is very important to study the 
pathophysiology of MPAN and search for potential therapies. 
 
Methods: We studied the pathophysiological alterations in MPAN using fibroblasts derived from three confirmed patients 
identified as MPAN1, MPANH and MPANB, the first two with the same mutation (p.Gly69Arg) and MPANB with another one 
(p.Gly58Arg) but all of them from different countries. In order to achieve this aim, pathophysiological mechanisms will be studied 
examining protein expression levels of several cellular pathways by Western blotting and iron accumulation by Prussian Blue 
staining. 
 
Results: We found iron accumulation and alteration of several pathways in the cellular models. In addition, we found two 
pharmacological cocktails that both reduced iron accumulation and corrected all pathological alterations.   
 
Conclusions: Fibroblast cell cultures derived from patients are interesting cellular models for both disease modelling and 
pharmacological screenings but it is neccesary further studies to confirm the results and to establish the mechanism of action of 
the two pharmacological cocktails and their use as medical therapies.  
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